Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
Want to see IN:BLISSGVS full AI Analyst Report?
Top Page
Bliss Gvs Pharma Limited
(BLISSGVS)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹523.00
▲(261.31% Upside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by solid financial fundamentals led by a conservative, improving balance sheet and better recent profitability/cash flow. Technicals are supportive due to strong trend strength, but very overbought momentum raises near-term reversal risk. Valuation is a headwind given the elevated P/E and low dividend yield.
Positive Factors
Conservative balance sheet
Low and declining debt with rising equity and assets provides durable financial resilience. This reduces refinancing and interest-rate risk, preserves capacity to fund manufacturing scale-ups or regulatory filings, and supports long-term strategic optionality like targeted M&A or capex.
Negative Factors
Volatile margins and earnings
Large swings in margins and episodic profit weakness undermine predictability of core earnings. For a generics/formulations business, persistent margin volatility signals exposure to pricing pressure, product mix shifts or one-off costs, complicating capital allocation and forecasting.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low and declining debt with rising equity and assets provides durable financial resilience. This reduces refinancing and interest-rate risk, preserves capacity to fund manufacturing scale-ups or regulatory filings, and supports long-term strategic optionality like targeted M&A or capex.
Read all positive factors
Bliss Gvs Pharma Limited (BLISSGVS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹51.48B
Dividend Yield0.28%
Average Volume (3M)104.36K
Price to Earnings (P/E)40.7
Beta (1Y)1.26
Revenue Growth7.19%
EPS Growth82.31%
CountryIN
Employees831
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.40
Shares Outstanding105,788,970
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bliss Gvs Pharma Limited Business Overview & Revenue Model
Company Description
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes a...
How the Company Makes Money
Bliss Gvs Pharma Limited primarily makes money by selling pharmaceutical formulations. Revenue is generated from (1) domestic sales in India, where products are distributed via the company’s sales/marketing network and channel partners to hospital...
Bliss Gvs Pharma Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
69
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.60B | 9.27B | 8.10B | 7.66B | 7.47B | 7.38B |
| Gross Profit | 3.95B | 5.02B | 3.96B | 2.49B | 3.50B | 3.47B |
| EBITDA | 2.07B | 2.35B | 1.27B | 1.49B | 1.35B | 762.37M |
| Net Income | 1.10B | 1.29B | 842.99M | 754.54M | 708.59M | 150.40M |
Balance Sheet | ||||||
| Total Assets | 14.00B | 14.92B | 13.01B | 12.14B | 11.57B | 11.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.01B | 2.27B | 1.41B | 1.41B | 684.11M | 1.35B |
| Total Debt | 524.91M | 217.50M | 881.04M | 998.40M | 1.02B | 1.09B |
| Total Liabilities | 2.32B | 2.61B | 2.09B | 2.11B | 2.39B | 2.62B |
| Stockholders Equity | 11.32B | 11.93B | 10.50B | 9.67B | 8.84B | 8.19B |
Cash Flow | ||||||
| Free Cash Flow | 483.04M | 818.87M | 298.48M | 1.24B | -594.86M | 614.77M |
| Operating Cash Flow | 775.52M | 1.39B | 1.06B | 1.52B | 343.13M | 1.35B |
| Investing Cash Flow | -272.20M | -382.80M | -754.41M | -1.33B | -77.51M | -929.75M |
| Financing Cash Flow | -448.06M | -892.11M | -303.45M | -208.93M | -249.38M | -237.30M |
Bliss Gvs Pharma Limited Technical Analysis
Positive
144.75
Price Trends
331.38
Positive
268.73
Positive
213.34
Positive
Market Momentum
43.46
Negative
79.40
Negative
93.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 144.75 is below the 20-day moving average (MA) of 423.23, below the 50-day MA of 331.38, and below the 200-day MA of 213.34, indicating a bullish trend. The MACD of 43.46 indicates Negative momentum. The RSI at 79.40 is Negative, neither overbought nor oversold. The STOCH value of 93.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.
Bliss Gvs Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹14.26B | 34.26 | ― | 1.24% | 6.89% | -23.34% | |
73 Outperform | ₹13.14B | 17.05 | ― | ― | 4.98% | 55.05% | |
71 Outperform | ₹51.48B | 40.69 | ― | 0.28% | 7.19% | 82.31% | |
67 Neutral | ₹17.67B | 30.40 | ― | 0.44% | 6.91% | 102.41% | |
64 Neutral | ₹17.28B | 25.64 | ― | 0.71% | 18.98% | 8.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹10.53B | 64.19 | ― | 0.24% | 12.61% | -61.60% |
* Healthcare Sector Average
IN:BLISSGVS
Bliss Gvs Pharma Limited
486.60
339.39
230.55%
IN:BAJAJHCARE
Bajaj Healthcare Ltd
312.80
-210.62
-40.24%
IN:HESTERBIO
Hester Biosciences Limited
2,076.80
326.42
18.65%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
212.35
-2.67
-1.24%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
13.98
-5.05
-26.54%
IN:WINDLAS
Windlas Biotech Ltd.
816.55
-55.69
-6.38%
Bliss Gvs Pharma Limited Corporate Events
Bliss GVS Pharma Triggers Open Offer as Anupam Rasayan Moves to Acquire Significant Stake
May 23, 2026
Bliss GVS Pharma Limited has disclosed that Anupam Rasayan India Limited has entered into a share purchase agreement with certain promoters and public shareholders to acquire equity shares of the company, triggering a mandatory open offer under In...
Bliss GVS Pharma Set for Change of Control as Anupam Rasayan to Acquire 43.3% Stake
May 23, 2026
Bliss GVS Pharma Limited has disclosed that its board has noted a Share Purchase Agreement under which Anupam Rasayan India Limited will acquire 4,58,03,024 equity shares, representing 43.30% of the company’s paid-up share capital, from a co...
Anupam Rasayan to Acquire 43.3% Stake in Bliss GVS Pharma, Triggers Open Offer
May 23, 2026
Bliss GVS Pharma Limited’s board has noted the execution of a Share Purchase Agreement under which Anupam Rasayan India Limited will acquire 4,58,03,024 equity shares, representing 43.30% of the company’s paid-up share capital, from a ...
Bliss GVS Pharma Clears FY26 Results, Declares 100% Final Dividend and Sets Virtual AGM
May 12, 2026
Bliss GVS Pharma Limited’s board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, together with an unmodified audit opinion, underscoring the integrity of its reported financia...
Bliss GVS Pharma Clears FY26 Results, Declares 100% Final Dividend
May 12, 2026
Bliss GVS Pharma Limited’s board has approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditors issuing an unmodified opinion, underscoring the integrity of the companyR...
Bliss GVS Pharma bolsters board with two new independent directors
Apr 3, 2026
Bliss GVS Pharma Limited has strengthened its board oversight by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. The appointments, re...
Bliss GVS Pharma Adds Two Independent Directors to Strengthen Board Oversight
Apr 3, 2026
Bliss GVS Pharma Limited has strengthened its board by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. Both appointees bring extensiv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.